EU/3/12/1002

About

This medicine is now known as ofranergene obadenovec.

On 6 June 2012, orphan designation (EU/3/12/1002) was granted by the European Commission to Gregory Fryer Associates Ltd, United Kingdom, for adenovirus-associated vector containing human Fas-c gene for the treatment of glioma.

In December 2015, Gregory Fryer Associates Ltd changed name to Envigo Pharma Consulting Ltd.

The sponsorship was transferred to Envigo CRS S.A., Spain, in April 2019.

Key facts

Active substance
Adenovirus-associated vector containing human Fas-c gene (ofranergene obadenovec)
Disease / condition
Treatment of glioma
Date of first decision
06/06/2012
Outcome
Positive
EU designation number
EU/3/12/1002

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Envigo CRS S.A.
Carrer Argenters 6
Santa Perpetua de Mogoda 08130
Spain
Tel. +34 9371 37045
http://www.envigo.com/contact-envigo/general-inquiry.aspx

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating